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Background: Dihydropyridine calcium channel blockers (CCBs) are more effective in reducing carotid intima-media
thickness (IMT) than other classes of antihypertensive drugs due to their vascular effects. However, the mechanism
remains to be elucidated.
Findings: Ox-LDL induced HUVSMCs proliferation in a time- and dose-dependent manner. When pretreated with
three CCBs before 50 μg/ml ox-LDL stimulation, 30 μM lacidipine and 3 μM amlodipine exhibited 27% and 18%
decrease of pro-proliferative effect induced by ox-LDL, whereas (S-)-amlodipine did not have any anti-proliferative
effect. 30 μM lacidipine inhibited about two-thirds of the ox-LDL induced ROS production in HUVSMCs, whereas
amlodipine and (S-)-amlodipine did not have influence on ROS production. The MAPKs pathway inhibitors inhibited
the ox-LDL induced proliferation of HUVSMCs.
Conclusion: Our study has demonstrated that lipophilic CCBs, such as lacidipine may inhibit ox-LDL induced
proliferation and oxidative stress of VSMCs, and that the ROS-MAPKs pathway might be involved in the mechanism.
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In our previous meta-analysis, we found that calcium
channel blockers (CCBs), mainly the dihydropyridine type,
were more effective in reducing carotid intima-media
thickness (IMT) than other classes of antihypertensive
drugs such as diuretics, β-blockers, and angiotensin-
converting enzyme (ACE) inhibitors [1]. This advantage
of CCBs might contribute to their superiority in the
prevention of stroke that had been repeatedly shown in
previous studies [2]. However, the mechanism for the
vascular advantage of CCBs remains to be elucidated.
IMT is a measure of vascular hypertrophy, which is in
part the consequence of media thickening. It is known
that the oxidized low-density lipoprotein (ox-LDL) chol-
esterol may induce oxidative stress of vascular smooth* Correspondence: jiguangw@gmail.com
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reproduction in any medium, provided the ormuscle cells (VSMCs) by activating the mitogen-activated
protein kinases (MAPKs) pathway, and in turn promote
proliferation of VSMCs [3,4] and hence vascular hyper-
trophy. The oxidative mechanism may increase formation
of intracellular reactive oxygen species (ROS), which may
behave as intracellular second messengers and modulate
expression of genes that influence the development of vas-
cular lesions [5]. We hypothesized that CCBs might exert
their vascular protective effect via the oxidative stress
pathway in VSMCs.
Several long-acting CCBs have been studied for their
vascular effects, and are frequently used in clinical practice
in many countries, such as amlodipine [6], lacidipine [7]
and azelnidipine [8]. These long-acting CCBs are indiffer-
ent in the blood pressure lowering effect, but different in
lipophilicity and hence the binding affinity with the cal-
cium channels inside the lipophilic cell membrane. Lacidi-
pine is highly lipophilic and has long-term blood pressure
lowering effect, even though its terminal elimination half-. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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http://www.biomedcentral.com/1756-0500/5/168life (t1/2z) is approximately 6–10.8 h [9]. The lipophilic
property of lacidipine can also be important in vascular
protection, because it apparently may interact with cells in
the absence of L-type calcium channels, and give lacidi-
pine vascular protection effects independent of its actions
on blood pressure [9]. Amlodipine is also lipophilic [7] but
less than lacidipine [9]. Amlodipine has two enantiomers.
It is known that only the (S-)-isomer of amlodipine has
blood pressure lowering effect, and has recently been avail-
able in the Chinese market as a separate drug from amlodi-
pine. However, there is some evidence that the (R+)-isomer
of amlodipine is not a simple bystander, but might exert
vascular protective effect, and play a role in the peculiar
protective effect of amlodipine [10,11], as repeatedly shown
in large randomized controlled trials in hypertension [2]
and coronary artery disease [7]. We therefore investigated
the effect of lacidipine, amlodipine and (S-)-amlodipine on
the ox-LDL induced proliferation and oxidative stress of
VSMCs.Results
Pro-proliferation of ox-LDL
To determine the right time and dosage of ox-LDL, we
examined effects induced by ox-LDL on various incubation
time and dosages. After 6, 12, 24 and 36 h of incubation
with ox-LDL (50 μg/ml), quiescent HUVSMCs were stimu-
lated proliferation in a time-course manner (Figure 1a). Ox-
LDL exerted pro-proliferative effects, at 12 h of incubation,
and the maximal effect at 24 h of incubation. After 24 h ofFigure 1 Time-course and dose-dependent effects of ox-LDL on HUVSM
employed. At the end of each experiment, a water-soluble tetrazolium salts (W
(a). Cells incubated with ox-LDL (50 μg/ml) in various periods. * P< 0.05 vs. co
of ox-LDL. (b). Cells exposed to various concentrations of ox-LDL, FBS (5%) or
control. NS indicates no significance vs. ox-LDL (50 μg/ml). Data are mean± S
expressed as fold increase of absorbance in 440 nm compared with unstimulaincubation with various concentrations of ox-LDL (6.25-
100 μg/ml), FBS (5%) or Ang II (10-7 M), HUVSMCs were
stimulated proliferation with ox-LDL also in a dose-
dependent manner (Figure 1b). Ox-LDL began to manifest
significant mitogenic effects at 6.25 μg/ml, and the max-
imal effect at 50 μg/ml. The maximal pro-proliferative
effect of ox-LDL after 24 h of incubation and at 50 μg/ml
of dosage was an approximately 60% (1.59± 0.13 fold) in-
crease in the proliferation of HUVSMCs, as compared with
that of unstimulated cells. This effect was similar to FBS
(1.56± 0.03) and slightly greater than Ang II (1.44 ± 0.03,
P=0.06). Further increasing time and concentrations of
ox-LDL co-incubation exerted cytotoxic or apoptotic effects
on VSMCs (data not shown).Effects of CCBs on cell proliferation
We then studied effects of three CCBs (lacidipine, amlo-
dipine and (S-)-amlodipine) on the ox-LDL induced
HUVSMCs proliferation. Cells were pretreated for 1 h
with the three CCBs or NAC (N-acetyl-L-cysteine, intra-
cellular reactive oxygen species scavenger) before the 24 h
of incubation with ox-LDL (50 μg/ml). 10 μM and 30 μM
lacidipine exhibited 21% (P< 0.001) and 27% (P< 0.001)
decreases of the pro-proliferative effect induced by ox-
LDL, respectively, and the anti-proliferative effect was
dose-dependent (P< 0.001, Figure 2a). 3 μM amlodipine
exhibited 18% (P=0.01) decrease, while (S-)-amlodipine
did not exhibit any anti-proliferative effect in our experi-
mental conditions at a concentration equal to amlodipineCs proliferation. During the experiment, medium with 0.4% FBS was
ST-1) assay was performed to quantify the number of proliferation cells.
rresponding 0 h control. NS indicates no significance vs. 24 h incubation
Ang II (10-7 M) as indicated. * P< 0.05 vs. corresponding no ox-LDL
D of three to six independent experiments determined in duplicate, and
ted cells.
Figure 2 Effects of three lacidipine (a), amlodipine and (S-)-amlodipine (b) and NAC on ox-LDL induced HUVSMCs proliferation. Cells
were pretreated for 1 h with or without CCBs or with NAC (5 mM), and then treated with or without ox-LDL (50 μg/ml). Data are mean± SD of
five to eight independent experiments determined in duplicate (three independent experiments for (S-)-amlodipine), and expressed as fold
increase of absorbance in 440 nm compared with unstimulated cells. * P< 0.05 vs. corresponding no ox-LDL control. # P< 0.05 vs. ox-LDL. NS
indicates no significance vs. corresponding solvent group (a) or vs. the control group (b).
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(P< 0.001) decrease. These CCBs at the dosages shown in
Figure 2 did not show significant effect on cell viability ex-
cept for 30 μM lacidipine on which cell viability was sig-
nificantly different from the control group (P=0.02) but
not from the solvent group (P=0.39). However, if further
increasing the dosage of three CCBs, cell viability signifi-
cantly decreased (data not shown).Effects of CCBs on cell ROS production
DCF (2′,7′ -dichlorofluorescein) production, detected by
a fluorescence microplate reader and expressed as fold in-
crease of fluorescence intensities compared with unstimu-
lated cells, represented the intracellular ROS generation.
Figure 3 shows that DCF production of HUVSMCs induced
by the incubation with ox-LDL (50 μg/ml) for 2 h tended
to be greater (P=0.07) than that by the incubation with
Ang II (10-7 M). When pretreated for 30 min with these
three CCBs and NAC, only 30 μM lacidipine (P=0.02)
and 5 mM NAC (P=0.03) exerted inhibition. Lacidipine
inhibited about two-thirds (P=0.02) of the ox-LDL induced
DCF production in HUVSMCs, with a potency similar
to NAC. 10 μM amlodipine inhibited about one-fifth
(P=0.46), and (S-)-amlodipine did not inhibit the ox-
LDL induced intracellular increase of DCF production.Effects of MAPKs inhibitors on cell proliferation
It is known that the MAPKs signaling pathway is involved
in the proliferation of VSMCs. Three MAPKs pathway
inhibitors, SB-202190 (10 μM, p38 MAPK inhibitor), SP-
600125 (10 μM, JNK inhibitor) and U-0126 (10 μM, MEK
inhibitor), were used as tool drugs to determine whether
the MAPKs pathway was involved in the ox-LDL induced
proliferation on HUVSMCs. Cells were pretreated with
the tool drugs for 1 h, and then incubated with ox-LDL
(50 μg/ml) for 24 h. All these three tool drugs inhibited
(35%–66% decrease, P< 0.001) the ox-LDL induced prolif-
eration of HUVSMCs (Figure 4). SB-202190 had the stron-
gest effect of inhibition. In the absence of ox-LDL, only
SB-202190, but not the other tool drugs, showed a signifi-
cant effect of inhibition in comparison with control.Discussion
Our study has demonstrated an anti-proliferative and
anti-oxidative effect of the lipophilic CCBs on HUVSMCs.
The most lipophilic CCB lacidipine may inhibit prolif-
eration and oxidative stress of VSMCs. Amlodipine also
inhibits proliferation but does not influence oxidative
stress, whereas its (S-)-isomer, (S-)-amlodipine, does not
have anti-proliferative, nor anti-oxidative effect. Our find-
ing may have clinical implications, because enhanced
Figure 4 Involvement of the MAPKs signaling pathway in the
effect of ox-LDL on HUVSMCs. Cells were pretreated for 1 h with
or without inhibitors of the MAPKs signaling pathway: SB-202190
(10 μM, p38 MAPK inhibitor), SP-600125 (10 μM, JNK inhibitor) and
U-0126 (10 μM, MEK inhibitor), and then treated with or without ox-
LDL (50 μg/ml). Data are mean± SD of four independent
experiments, and expressed as fold increase of absorbance
compared with unstimulated cells. * P< 0.05 vs. control. # P< 0.05
vs. ox-LDL. ** P< 0.05 vs. control. NS indicates no significance vs.
control.
Figure 3 Ox-LDL and Ang II induced ROS generation in
HUVSMCs and effects of three CCBs (lacidipine, amlodipine and
(S-)-amlodipine) and NAC. Cells were pretreated for 30 min with
or without CCBs or with NAC (5 mM), and then treated with Ang II
(10-7 M) or ox-LDL (50 μg/ml) for 1.5 h. Then, the DCFH-DA (10 μM)
probe was added and incubated away from light for another
30 min. Thereafter, cells were immediately washed twice with PBS,
and added to 400 μL DMEM, and the fluorescent intensity was read
five times and averaged. The excitation wavelength is 504 nm, and
the emission wavelength is 529 nm. Data are mean± SD of five to
eight independent experiments determined in duplicate (three
independent experiments for (S-)-amlodipine), and expressed as fold
increase of DCF fluorescence intensities compared with unstimulated
cells. * P< 0.05 vs. corresponding no ox-LDL control. # P< 0.05 vs.
ox-LDL. NS indicates no significance vs. ox-LDL.
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proliferative/secretory phenotype may contribute to the
pathogenesis of atherosclerosis, restenosis after angioplasty,
and graft atherosclerosis after coronary transplantation
[12,13], and because intracellular ROS regulates pheno-
typic differentiation of VSMC [14].
Similar anti-proliferative and anti-oxidative effects of
lacidipine had been observed on other cell lines. In
human umbilical vein endothelial cells, lacidipine might
decrease NF-κB-mediated and ox-LDL induced adhesion
molecule expression [15]. This effect of lacidipine might
be the consequence of its influence on the intracellular
ROS formation induced by ox-LDL [16].
In keeping with several previous studies [17-19], our
study showed that amlodipine might also inhibit VSMC
proliferation. However, we only observed a weak and non-
significant anti-oxidative effect of amlodipine, which was
different from the results of previous studies [19,20].
Other mechanisms than the anti-oxidative effect might be
involved in the anti-proliferative effect of amlodipine, such
as, calcium signaling through ERK1/2 cascade, nitric oxide
(NO) production, modulation of matrix metalloprotei-
nases activity, etc. [19].At least one previous study suggested that the vas-
cular effect of amlodipine was attributable to the ac-
tion of its (R+)-isomer, which had no effect on blood
pressure [10]. In endothelial cells, which had no cal-
cium channels, (R+)-amlodipine, but not (S-)-amlodipine
might activate NO synthase and promoted the production
of NO [10,11]. In our study in VSMCs, (S-)-amlodipine
did not inhibit ox-LDL induced proliferation and oxidative
stress of HUVSMCs. The distinct effect of amlodipine
and (S-)-amlodipine is not understood. It is possible that
(R+)-amlodipine and (S-)-amlodipine have different lipo-
philicities, and hence have different vascular effects. Tak-
ing into account the strong effect of the highly lipophilic
CCB lacidipine, this explanation is very likely.
We also studied the role of ROS in the proliferation of
VSMCs by the use of NAC, a ROS scavenger, and the
role of the MAPKs signaling pathway by the use of the
distinct inhibitors of this pathway. Our finding of these
experiments suggested that the ROS-MAPKs pathway
might be one of mechanisms for the effect of CCBs on
proliferation of VSMCs. This mechanism may also ex-
plain why lacidipine has strong anti-proliferative effect.
The dihydropyridine ring of the higher lipophilic CCBs,
such as lacidipine, facilitates proton-donating and reson-
ance-stabilization mechanisms that quench the free rad-
ical reaction, thereby blocking the peroxidation process
and ROS production [21].
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In conclusion, our study has demonstrated that lipophilic
CCBs, such as lacidipine may inhibit ox-LDL induced pro-
liferation and oxidative stress of VSMCs. Although our
finding is in line with the results of previous animal studies
[22,23] and human research [6,24] on the vascular effects
of CCBs, further studies in animals and humans are still
required to compare these long-acting CCBs at similar
blood pressure lowering dosages.Methods
Chemicals and reagents
In our experiments, three CCBs were employed. Laci-
dipine (courtesy of GlaxoSmithKline China, Shanghai,
China) was dissolved in the mixture of Tween-80 and
ethanol (2:8). Amlodipine (a 1:1 mixture of two enan-
tiomers; courtesy of Pfizer China, Shanghai, China) and
(S-)-amlodipine (courtesy of Shihuida, Changchun, China)
were all dissolved in dimethyl sulfoxide (DMSO). Ox-LDL
(about 1.6 mg/ml) was purchased from UnionBiol (Beijing,
China), and the extent of the LDL oxidation was deter-
mined by measuring the levels of thiobarbituric acidreac-
tive substances (TBARS). SB-202190 (an inhibitor of p38
MAPK), SP-600125 (an inhibitor of JNK) and U-0126
(an inhibitor of MEK) were purchased from CalBiochem
(San Diego, California, USA). The following chemicals
were purchased from Sigma-Aldrich (Shanghai, China):
Angiotensin II, NAC, 2′, 7′-dichlorofluorescin diacetate
(DCFH-DA), DMSO and Tween 80. We also purchased cell
proliferation reagents WST-1 (Roche, Basel, Switzerland),
fetal bovine serum (FBS; Invitrogen, California, USA) and
Typan Blue (Beyotime, Jiangsu, China).Cell culture
Human umbilical vein smooth muscle cells (HUVSMCs)
were obtained from the Health Protection Agency Culture
Collections (Porton Down, Salisbury, UK). Cells were
grown in Dulbecco’s Modified Eagle Medium (DMEM) of
high glucose supplemented with 10% FBS without anti-
biotics. The cells were maintained 37°C in a 5% CO2 in-
cubator. The medium was changed every 2 days. Cells
were digested with 0.25% trypsin and 0.02% EDTA when
cells reached 70-80% confluency, and were serum-deprived
in DMEM with 0.1% FBS for 24 h before each experi-
ment when cells reached 60-70% confluency. After serum
deprivation, the cells were treated with reagents, pharma-
cological inhibitors and treatment drugs as noted in the
figure legends. During the period of experiment, medium
with 0.4% FBS was employed for the maintenance of cell
viability. Trypan blue exclusion test was applied to detect
cell viability. On our experimental conditions, cell viabil-
ity after each experiment was always greater than 95%.Cell proliferation assay
In order to determine the effect of a compound on cell
growth, serum-starved cells at a density of 1 × 104 cells/
well were incubated on 24-well plates for 24 h followed
by another 2.5 h of incubation with water-soluble tetra-
zolium salts (WST-1). The tetrazolium salts were cleaved
to soluble formazan by intracellular mitochondrial dehy-
drogenases in the sample. This augmentation in enzyme
activity led to an increase in the amount of formed for-
mazan dye, which was directly correlated with the num-
ber of proliferative cells in the culture. Quantification of
the formazan dye produced by metabolically active cells
was measured at 440 nm wavelengths by scanning the
multiwell spectrophotometer. Because various concen-
trations of 2 different solvents were used for these experi-
ments, we set a solvent-only control group for each of the
2 different solvents at higher concentrations.
Detection of intracellular ROS
DCFH-DA is a dye that allows monitoring of ROS by the
fluorescence microplate spectrophotometer. This method
is based on the oxidation of DCFH-DA by ROS, resulting
in the formation of the fluorescent compound DCF. Serum-
starved cells in 24-well plates were preincubated with the
three CCBs and NAC for 30 min as described above, and
ox-LDL (50 μg/ml) was then added to the medium for
1.5 h. DCFH-DA (10 μM) probe was then added and incu-
bated for another 30 min. Thereafter, cells were immediately
washed twice with PBS and added to 400 μl DMEM. The
fluorescent intensity was read five times and averaged. The
excitation wavelength was 504 nm, and the emission wave-
length was 529 nm.
Statistical analysis
Values were mean± SD. Means were compared by one-
way ANOVA with the post hoc test for multiple compari-
sons (Dunnett’s test for comparison of a single control or
Bonferroni correction for pairwise comparisons). P< 0.05
was considered statistically significant.
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